FDA approves drug touted as first to delay progression of Alzheimer’s disease
On behalf of those impacted by Alzheimer’s disease, the Alzheimer’s Association enthusiastically welcomes the June 7 historic FDA approval of aducanumab (Biogen/ Eisai) for tre...
